Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution

Completed

Conditions studied: Bleeding Reduction

In brief

This study will help enhance current understanding of the impact of Acute Normovolemic Hemodilution (ANH) administration on transfusion requirements post cardiac surgery, the effect of this procedure on coagulation, and platelet hemostasis, and the amount of chest tube drainage 24 hours post coronary artery bypass graft surgery (CABG) surgery.

Key facts

Study ID

NCT03326323

Run by

Inova Health Care Services

People needed

43

Starts

2018-03-19

Expected to finish

2019-10-17

Last updated by the study team

2020-01-13

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• . Subject is 18-85 years old.
• . Subject is hemodynamically stable
• . The subject is able to read and has signed and dated the informed consent document including Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization permitting release of personal health information as approved by the investigator's Institutional Review Board (IRB).

You may not qualify if…

• . Hematocrit <30 at baseline
• . Insufficient (Low) on pump hematocrit of < 21%
• . Patient is hemodynamically unstable
• . Patient requiring an emergency procedure
• . Left main coronary artery stenosis with evidence of hemodynamic instability (e.g.. hypotension, ST segment elevations on electrocardiogram)
• . Aortic valve stenosis with evidence of hemodynamic instability (e.g.. hypotension, ST segment elevations on electrocardiogram)

Where it is running

• Inova Heart and Vascular Institute — Falls Church, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.